D. Krasnojon
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 10%
- Breast Cancer Treatment Studies
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 7
- Colorectal Cancer Treatments and Studies 3
- HER2/EGFR in Cancer Research 3
- PARP inhibition in cancer therapy 1
-
- Advanced Breast Cancer Therapies 2
- Co-authors
- Alicia Clawson (8 shared papers)Sergey Cheporov (9 shared papers)G. Manikhas (5 shared papers)Paul Bhar (7 shared papers)William J. Gradishar (3 shared papers)А. Н. Махсон (3 shared papers)José Iglesias (1 shared paper)John R. McGuire (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Clinical Breast Cancer (1 paper)Cancer Research (1 paper)European Journal of Cancer (1 paper)European Journal of Cancer Supplements (2 papers)
- Partner nations
- RussiaUnited States
In The Last Decade
D. Krasnojon
9 papers receiving 385 citations
Peers
Comparison fields: 5 of 47
- Oncology 348
- Cancer Research 160
- Dermatology 30
- Biomaterials 40
- Pulmonary and Respiratory Medicine 77
Countries citing papers authored by D. Krasnojon
This map shows the geographic impact of D. Krasnojon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Krasnojon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Krasnojon more than expected).
Fields of papers citing papers by D. Krasnojon
This network shows the impact of papers produced by D. Krasnojon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Krasnojon. The network helps show where D. Krasnojon may publish in the future.
Co-authors
The 15 scholars most cited alongside D. Krasnojon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 260 | |
| 2 | 2012 | 91 | |
| 3 | 2007 | 25 | |
| 4 | 2011 | 8 | |
| 5 | 2008 | 6 | |
| 6 | 2007 | 2 | |
| 7 | 2011 | 2 | |
| 8 | 2011 | 1 | |
| 9 | 2008 | 1 |
About D. Krasnojon
D. Krasnojon is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Biomaterials, having authored 9 papers that have together received 396 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Colorectal Cancer Treatments and Studies (3 papers), HER2/EGFR in Cancer Research (3 papers), Advanced Breast Cancer Therapies (2 papers), Cell death mechanisms and regulation (2 papers), Breast Cancer Treatment Studies (2 papers), PARP inhibition in cancer therapy (1 paper) and Nanoparticle-Based Drug Delivery (1 paper). The work is most often cited by research in Oncology (348 citations), Cancer Research (160 citations), Dermatology (30 citations), Biomaterials (40 citations) and Pulmonary and Respiratory Medicine (77 citations). D. Krasnojon has collaborated with scholars based in Russia and United States. Frequent co-authors include Alicia Clawson, Sergey Cheporov, G. Manikhas, Paul Bhar, William J. Gradishar, А. Н. Махсон, José Iglesias, John R. McGuire, WJ Gradishar and Michael Hawkins. Their work appears in journals such as Journal of Clinical Oncology, Clinical Breast Cancer, Cancer Research, European Journal of Cancer and European Journal of Cancer Supplements.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.